|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||5.39 - 5.97|
|52 Week Range||3.84 - 30.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Acreage Holdings Inc. said Friday it has secured financing that is non-dilutive to its planned equity deal with Canadian cannabis company Canopy Growth Corp. . The company said it has secured a $100 million credit facility with a $50 million private loan partly provided by Chief Executive Kevin Murphy to act as cash collateral, and completed a private placement of $30 million in warrants. The company can draw down an initial $49 million of the credit facility, giving it immediate funds of about $79 million. The deals "significantly improve Acreage's financial position to continue to execute on its vision while establishing paths for further additional non-dilutive and shareholder-friendly financing transactions," the company said in a statement. Canopy, the market leader thanks to a $4 billion investment from drinks giant Constellation Brands Inc. , has a deal that will allow it to take over Acreage once cannabis restrictions in the U.S. have been eased. Acreage is a multi-state operator that is headquartered in New York City with operations in 20 states. MKM analyst Bill Kirk welcomed the news. "Given the language around future financing in the release, we believe Acreage will continue to have access to capital as needed," he wrote in a note. "Where many have struggled to find any form of capital, Acreage is secure." Acreage shares were down 7% after the news, and have fallen 75% in the last 12 months, while the ETFMG Alternative Harvest ETF has fallen 55% and the S&P 500 has gained 23%.
More than 10,000 securities trade on OTC Markets. Broken up into three tiers—OTCQX, OTCQB, and Pink—the OTC Markets connect U.S. investors with issuers from 38 countries and dozens of emerging industries. ...
The next four to six months will be tumultuous for the cannabis sector, pricing pressure will continue and about 50% of companies with Canadian licenses are facing bankruptcy. Those were some of the talking points at day two of the ICR Conference in Orlando, Fla., according to MKM analyst Bill Kirk, who highlighted the subdued tone at the event in an early note to investors. "With years of reckless spending, less growth than expected, limited access to capital markets, excess supply, and uncompetitive pricing (to illicit market), we generally agree," Kirk wrote. "And while there may be opportunities on the other side of the looming shakeout, we can't get excited about sector-wide upside." The analyst named Acreage and Flowr as two companies in attendance that he rates as buy. Acreage stock offers a wide discount to the deal price (the company will be acquired by Canopy Growth Corp. as soon as cannabis restrictions in the U.S. are lifted) and is improving profitability as states mature, he wrote. Flowr has fewer supply issues in the Canadian premium market and has better mix exposure to Portugal and Germany, he wrote. Kirk has neutral ratings on Tilray and Cronos . "It is very likely the negative outlook shared at ICR will come to fruition. Acreage and Flowr are opportunities within this set-up largely because they operate outside many of the issues," said the note. The ETFMG Alternative Harvest ETF has fallen 41% in the last 12 months, while the S&P 500 has gained 26%.
After the illnesses and deaths rose through the summer and fall, the CDC said that cannabis vaping products bought off the illicit market were "linked to most of the cases ..."
Following the final release of Opportunity Zone regulations on December 19, investors in cannabis dispensaries stand to benefit, some say.
The MGO and ELLO Cannabis Practice recently launched its “The Cannabis 50” list. This industry highlight recognizes those who transformed, uplifted and inspired the growth and maturation of the cannabis ...
DETROIT — The premier gathering of cannabis entrepreneurs and investors in North America, the Benzinga Cannabis Capital Conference , is heading to Miami in 2020 for its sixth installment. The conference, ...
Every year, the movers and shakers in the cannabis industry gather in Las Vegas for a week of events and networking. This year, one of the longest-standing award shows in the space, The Cannabis Business ...
Last week saw a landmark decision by the U.S. House Judiciary Committee, which approved a bill advocating the decriminalization of marijuana at the federal level. Pending approval by the House of Representatives and Senate, this could mean full scale legalization in the U.S.The good news instigated a bit of a rally across cannabis stocks, and a timely one at that, too. The cannabis industry has had a rough ride this year, with many leading names struggling in the market due to a variety of reasons, from retail delays to congestion at the wholesale level to regulatory uncertainty.The cannabis industry is still in its nascent stages, and the young sector is still finding its feet. Seaport Global’s Brett Hundley has been keeping a close eye, noting, “The breadth of product offering rushing to market is incredibly wide and diverse. The prospect of trying to pick winners and losers at this juncture is challenging, to say the least.”With Q3 reports recently filed, Hundley decided to reassess his position on three cannabis stocks, which have seen their prices trend downward this year. Let’s have a look at some of the analyst’s findings.Aurora Cannabis (ACB)“I believe the children are our future,” so the song goes. Aurora Cannabis hopes so too, as ACB is the most held stock on millennial user-heavy investing app, Robinhood.Popularity, though, doesn’t always equate to success. Aurora, the world’s second largest cannabis company, recently experienced a sell-off following a disappointing earnings report.Following Aurora’s earnings report, Hundley has updated his financial model, noting “Our new model includes a draw-down of forward production expectations, offset by an improved pricing assumption. As a result, our forward sales forecasts move higher, including new FY2020 and FY2021 estimates of $400.5MM and $522.2MM, respectively. We now expect a deeper-than-anticipated EBITDA loss in FY2020, built mainly on a higher SG&A assumption. We now project an EBITDA loss of $98.8MM in FY2020, followed by a forecasted loss of $33.8MM in FY2021.”As a result, Hundley reiterates a Neutral rating (i.e. "hold") on Aurora stock without providing a price target. (To watch Hundley's track record, click here)The rest of the Street’s take is split on Aurora. 5 Buy ratings, 5 Holds, and 2 Sells received in the last three months give the cannabis giant a Moderate Buy analyst consensus. Is Aurora stock overvalued or undervalued based on these ratings? The average price target stands tall at $4.97, putting the upside potential at a hefty 99%. (See Aurora stock analysis on TipRanks)Tilray (TLRY)Canadian cannabis company, Tilray, has led the charge on several fronts. The company was the first medical cannabis producer in North America to be GMP certified, the first cannabis company to IPO on the Nasdaq, and the first Canadian cannabis company to legally export medical cannabis to the U.S. for a clinical trial.As the saying goes, though, you’re only as good as your last performance, and the Tilray show has not been without its share of glitches over the last year.Year-to-date, the cannabis producer’s share price has tumbled down, losing roughly 70% of its value. A negative cash flow and the acquisition of the world’s largest hemp foods manufacturer, Manitoba Harvest, completed earlier this year, have exerted heavy downward pressure.The company’s recent quarterly report was a mixed bag too, reporting slightly better-than-expected revenues for the quarter, but with the company still heavily in the red. Management has said it expects to achieve positive EBITDA by Q420.Hundley, though, is a bit more conservative and has updated the financial model for Tilray. The analyst said, “We now forecast an EBITDA loss of $23.3MM for 2020 along with positive EBITDA of $29.3MM for FY2021. Previously, we believe that management was willing to invest at continued losses in order to grab global market share, ahead, however we think that near-term market challenges have forced it into a drive for profitability, like many others in the space.” The analyst added, “We do like the company’s positioning as a global enterprise capable of producing brands or value-added ingredients for CPG/pharma partners. This gives the company multiple options, depending on how the overall global cannabis market evolves.”Accordingly, Hundley maintained a Neutral rating on TLRY, without offering a stock-price forecast. All in all, 3 Buys and 6 Holds assigned over the last 3 months add up to a Moderate Buy consensus on Tilray. The average price target, though, is $29.57, indicating a potential twelve-month gain of 45% from its current price. (See TLRY stock analysis on TipRanks)Acreage Holdings (ACRGF)You can tell times have changed when you look at a cannabis manufacturer’s board of directors, and find a former Republican Congressman, a former IBM CFO, and a former conservative Prime Minister among its board members. That’s what you get, though, at Acreage Holdings.Still, the big names haven’t helped the Canadian cannabis producer in the market this year, its chart a reflection of the difficulties the cannabis industry has faced– an unremitting ride to the bottom, whilst shedding more than 70% of its value.Earlier this year, the multi-state operator completed the acquisition of Form Factory, a multi-state manufacturer and distributor of cannabis-infused beverages and edibles. Acreage also agreed to a deal with Canopy Growth, the world’s largest cannabis company, who will purchase all of Acreage’s shares for $3.4 billion. The deal will be concluded in the future and is subject to the legalization of cannabis by the U.S. government.The company’s Q3 earnings report was slightly underwhelming and missed out on the Street’s estimates. Hundley recently updated his model on Acreage, too, noting, “Forward sales projections come down; however we are also moderating anticipated EBITDA losses, ahead. For FY2020, we now project sales of $221.8MM alongside an EBITDA loss of $3.4MM.” Further adding, “ACRGF remains focused on expanding its footprint across a wide swath of US states, and it believes that it will continue to garner access to various types of financing, in part related to its relationship with CGC.”To this end, the analyst reiterated a Buy rating on ACRGF, though slightly lowering the price target from $15 to $14. This still implies very healthy upside potential of 176%.According to TipRanks, the consensus on Wall Street is that ACRGF stock is a “hold” for investors. But TipRanks might as well have said “buy” — because analysts, on average, think the stock, currently at $5.05, could zoom ahead to $15.33 within a year, delivering 200% profits to new investors. (See Acreage stock analysis on TipRanks)
It's looking like cannabis stocks just might have bottomed out, and it has been a long time coming. In this week's episode of "Moneyline," Matt McCall wants investors to know that if they have a long-term perspective, the fundamentals really do matter. That's why he's still confident in pot despite its serious shellacking.Well, why's that? Just this week, the U.S. House of Representative's Judiciary Committee approved a bill that legalizes marijuana at the federal level. Many analysts say it's likely the bill will pass the Democrat-controlled House, but it faces a tougher battle in the Senate. But that doesn't matter. The existence of the bill itself is still a good sign for cannabis investors. McCall is declaring 2020 the year of cannabis -- politicians just need to wake up. He argues such legislation would essentially solve the vaping crisis and clear up issues with black-market marijuana.So how can investors play this week's good news? Start with U.S. cannabis companies. Take a look at Charlotte's Web (OTCMKTS:CWBHF) and Acreage Holdings (OTCMKTS:ACRGF). Those companies, along with a few others, are reporting annualized revenue between $100 million and $200 million. McCall says now is a perfect opportunity to build on existing positions in these names or add new ones, as these stocks have bright futures ahead. And while he's still a fan of the big Canadian names, there are better opportunities to get lit right now.InvestorPlace - Stock Market News, Stock Advice & Trading Tips McCall's PodcastThere's another emerging trend that McCall is big on: biotech stocks. There's one name in particular, Crispr Therapeutics (NASDAQ:CRSP), that's making big waves. CRSP stock is up an amazing 120% year-to-date -- and McCall identified this name earlier in 2019 as part of his Early Stage Investing portfolio for its potential in gene editing. * 7 Companies Using Artificial Intelligence to Outperform the Market This week's news easily justified CRSP's place in that portfolio. On Nov. 19, Crispr announced that patients receiving its CTX001 gene-editing therapy were experiencing significant benefits. This therapy is specifically designed for patients with severe blood disorders, and works by singling out and editing affected cells. One patient living with a form of beta thalassemia had been dependent on blood transfusions, receiving as many as 16 a year. After nine months with CTX001, that patient is now considered transfusion independent.McCall is particularly interested in the treatment's use in patients with sickle cell disease, a blood disorder that causes severe pain. And based on his recent travels to Lisbon, Portugal, healthcare will soon evolve to cure these diseases. In the future, he believes they'll even be cured at the embryonic level.So what else did he learn in Portugal? Tune in to "Moneyline" for more on his travels and the future of healthcare as it relates to artificial intelligence.Matthew McCall left Wall Street to actually help investors -- by getting them into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. Matt does not directly own the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Companies Using Artificial Intelligence to Outperform the Market * 7 Earnings Reports to Watch Next Week * 6 Retail Stocks Dropping Hard Ahead of Black Friday The post Consider Adding New Positions in U.S. Cannabis Stocks appeared first on InvestorPlace.
This week was a rough one for slow-burning Canadian marijuana stocks. Headlines of big-name companies' miserable earnings dominated financial media coverage. But don't let Cronos Group's (NASDAQ:CRON) revenue miss and the post-earnings drop in CRON stock get you down. In this week's episode of "Moneyline," Matt McCall is here to reassure you that the long-term potential is still there. For now, you may just want to look to our home-grown American pot companies.Earlier this week, Cronos reported adjusted losses per share of 2 cents, actually beating estimates. But it seems like investors were more concerned with CRON's revenue of $10.1 million, which missed estimates of $10.45 million.For McCall, the biggest problem with CRON stock isn't its short-term performance. Heck, in the next five years, he's positive that marijuana will be legal at the federal level in the U.S. That will be a huge catalyst for struggling stocks. But to him, that doesn't completely justify Cronos' $2.2 billion market capitalization.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut just across the border in the United States, two marijuana stocks reported earnings worthy of even short-term optimism. Acreage Holdings (OTCMKTS:ACRGF), most famous for its pending deal with Canopy Growth (NYSE:CGC), reported revenue of $22.4 million. What's the catch? Acreage's market cap is just $340 million. And Charlotte's Web (OTCMKTS:CWBHF), one of McCall's favorite companies, reported the upcoming opening of a 136,000 square foot facility. That shows it's clearly ready to keep scaling. * 7 Silver and Gold Stocks to Buy That Offer Contrarian Upside So don't let the headlines ruin your high just yet. As U.S. politicians debate federal legalization and the Food and Drug Administration works on reviewing the medical benefits of cannabidiol, investors should sit back and give marijuana stocks some time. McCall's PodcastSo, maybe you don't like marijuana stocks or pot in general. But what if you're an avid coffee drinker? Earlier in the year, McCall visited China to do boots-on-the-ground research. There, he checked in on recent IPO Luckin Coffee (NASDAQ:LK). After visiting a shop in Shanghai and tasting what LK had to offer, he wasn't initially impressed. But now, after Luckin reported revenue growth of 540% quarter-over-quarter, he's starting to sip on what LK stock has to offer.This company, often known as the Starbucks (NASDAQ:SBUX) of China, isn't the only hot stock he's starting to watch. Tune into this episode for three to watch -- and learn which one he sees as a "screaming buy." These three names, Sherwin-Wiliams (NYSE:SHW), Allegiant Travel (NASDAQ:ALGT) and Lululemon (NASDAQ:LULU) all play on big long-term themes that have him excited. And if you know McCall, you know he loves to invest based on these intense long-term trends.Make sure to listen in to this episode of "Moneyline" for more on stocks to watch and his reviews of Luckin Coffee's brew. Plus, you'll even get a preview of his recent travels to Portugal.Matthew McCall left Wall Street to actually help investors -- by getting them into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and+1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. Matt does not directly own the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Silver and Gold Stocks to Buy That Offer Contrarian Upside * 7 Earnings Reports to Watch Next Week * 5 Online Retail Stocks to Buy on the Dip The post Investors Can Still Get High on American Marijuana Stocks appeared first on InvestorPlace.
While some market analysts point to a blue wave being value destructive to the overall market, it could boost cannabis stocks, says CFRA's Garrett Nelson.
Acreage Holdings, Inc. (CSE: ACRG.U) (OTC: ACRGF) posted third-quarter revenue Tuesday of $22.4 million, up by 307% from the same quarter in the previous year. The company also posted a net loss attributable to Acreage of $39.9 million, or a 45-cent loss per share, which compares to a net loss of $4.51 million and 6 cents per share in the third quarter of 2018. The cannabis company's adjusted net loss was $15 million versus an adjusted net loss of $8.7 million in the corresponding period of 2018.
Cannabis business network Leafwire this week launched Leafwire Jobs, featuring 100% cannabis and hemp industry jobs. The job platform is free for all job seekers. “A job board has been by far the #1 requested feature from our member base over the past year," Leafwire CEO Peter Vogel said.
Cannabis operator Acreage Holdings, Inc (CSE:ACRG.U) (OTC: ACRGF) announced Friday the closing of a sale-leaseback deal worth around $72 million with GreenAcreage Real Estate, a cannabis-focused REIT. The deal calls for GreenAcreage to provide up to about $43.9 million in additional funding to properties in Florida and Illinois. “Acreage Holdings took a long, hard look at our portfolio of real estate holdings and made a strategic decision to rationalize our business strategy.
Most major cap-weighted indexes are rebalanced quarterly, semi-annually, or annually. This rebalancing consists of adding and removing securities based on market cap fluctuations throughout the quarter. ...
The plummet in the value of big cannabis stocks this year is not a signal that opportunities in the industry are over, Acreage Holdings Inc. (OTC: ACRGF) CEO Kevin Murphy said Tuesday. Speaking at the Benzinga Cannabis Capital Conference in Chicago, Murphy, the head of one of the biggest publicly traded cannabis companies, said he’s been around a long time and seen ups and downs before. Acreage is among the companies that has been in a free fall over the last six months after a couple years when cannabis stocks were darlings of the market.
Like the cannabis sector in general, Canopy Growth (CGC) trades near multi-year lows. At the current price of $22.75, the stock isn’t the favorite in the sector, but the deal to buy Acreage Holdings (ACRGF) in the future offers a backdoor play into Canopy Growth at a substantial discount to current market prices. The recent inside purchases of the Acreage CEO should highlight the clear path for investors to follow.Acreage CEO Insider PurchasesIn the last week, Acreage hit new lows in the $6s. Amazingly, the U.S. multi-state operator (MSO) traded at $30 in the last year.The cannabis stock is so out of favor that a premium right to purchase on the books from Canopy Growth isn’t helping the stock. For this reason, the open market stock purchases by Chairman and CEO Kevin Murphy are very meaningful.On October 8, the CEO bought an additional 100,000 shares at an average price of $6.85 per share for a total purchase price of $685,000. Mr. Murphy has previously bought another 154,000 shares back in July for a total purchase of 254,000 shares.Canopy Growth PathThe best part of a long-term investment in Canopy Growth is that the company has the best balance sheet in the business with a cash balance of $2.3 billion. The large Canadian LP can survive any prolonged downturn in the business and would benefit from some reduced competition in the cannabis space.The opportunity here is for investors to buy Acreage with a likely path to convert those shares into Canopy Growth shares at a far better price. Once cannabis is federally legal in the U.S., Canopy Growth will close their right to acquire Acreage based on the merger agreement.The deal is for Acreage shareholders to obtain 0.5818 shares of Canopy Growth for each share owned. With Canopy Growth trading at $22.75, Acreage would have a conversion value of $13.24 or 95% upside from the current stock price of only $6.80.In the meantime, an investor owns a U.S. MSO busy integrating Canopy’s IP, brands, and technologies across their U.S. operations. Despite licenses or consulting contracts for operations in 20 states, the stock has a listed market value of only $800 million while analysts expect the company to top 2020 revenues of $430 million.The main reason the stock offers such a large premium on closing of the Acreage deal is that the U.S. MSO stocks have generally become very cheap. Vaping concerns, regulatory approval questions and capital fears have all become drags on the sector still in major growth mode.Consensus VerdictOverall, Canopy has had 10 bullish analysts in its corner over the last three months, with 6 analysts playing it safe on the sidelines. The 12-month average price target of $36.36 showcases 76% in upside potential for the stock. (See Canopy stock analysis on TipRanks)TakeawayThe key investor takeaway is that Acreage Holdings offers a very cheap way to enter into a position in Canopy Growth. The large Canadian LP has numerous challenges in the current market environment where the company spent wildly for a global cannabis market that hasn’t fully developed yet, but the company has the cash for the long term. The current merger value has Canopy Growth only worth about twice the cash balance.An investor in Acreage obtains a cheap stock and immediate upside on federal approval of cannabis while benefiting from the protection of the large cash position of Canopy Growth. CEO Kevin Murphy has signaled the time to buy the stock is now.
With the launch of what's known as Fund III, the firm is changing its name to Entourage Effect Capital, in reference to the synergistic effect produced by different cannabinoids in the human body when consumed in combination with each other. The objectives of Fund III will be primarily focused on advancing cannabis businesses as diverse as science and bioscience operators, license aggregators, vertically integrated licensed operators and retailers as well as consumer packaged goods, biotech, ag-tech, media, technology and ancillary services.
The legalization of weed in Illinois has been well received by consumer spending with nearly $20 million on marijuana products being sold in the first 12 days. High Times CEO Stormy Simon joins On The Move to discuss.
Marijuana stocks are trying to end on a high note this week. Alternative Harvest had its best day of 2019 on Thursday, closing up more than 8%. Yahoo Finance’s Adam Shapiro, Julie Hyman, Brian Cheung, and Pras Subramanian break down the strong week for the cannabis industry on On The Move.